Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03663933 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
A Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 2
- Study locations
NCT03663933 is a Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 71 participants, below the 149-participant average among 18 other Immune System Diseases trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03663933, a Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Blood stem cells in the bone marrow make all the cells to normally defend a body against disease. Allogeneic blood or marrow transplant is when these stem cells are transferred from one person to another. Researchers think this treatment can provide a new, healthy immune system to correct T-cell problems in some people. Objective: To see if allogeneic blood or bone marrow transplant is safe and effective in treating people with T-cell problems. Eligibility: Donors: Healthy people ages 4 and older Recipients: People the same age with abnormal T-cell function causing health problems Design: All participants will be screened with: * Medical history * Physical exam * Blood, heart, and urine tests Donors will also have an electrocardiogram and chest x-ray. They may have veins tested or a pre-anesthesia test. Recipients will also have lung tests. Some participants will have scans and/or bone marrow collected by needle in the hip bones. Donors will learn about medicines and activities to avoid and repeat some screening tests. Some donors will stay in the hospital overnight and have bone marrow collected with anesthesia. Other donors will get shots for several days to stimulate cells. They will have blood removed by plastic tube (IV) in an arm vein. A machine will remove stem cells and return the rest of the blood to the other arm. Recipients will have: * More bone marrow and a small fragment of bone removed * Dental, diet, and social worker consultations * Scans * Chemotherapy and antibody therapy for 2 weeks * Catheter inserted in a chest or neck vein to receive donor stem cells * A hospital stay for several weeks with more medicines and procedures * Multiple follow-up visits
Conditions Studied
Interventions
- DRUG GVHD Prophylaxis
- DRUG e-ATG
- PROCEDURE Immunosuppression Only Conditioning
- PROCEDURE Reduced Intensity Conditioning
- PROCEDURE Allogeneic HSC
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Minnesota
- National Marrow Donor Program - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2030-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03663933
The ClinicalTrials.gov registry entry for NCT03663933 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 149-participant average among 18 other Immune System Diseases trials with a reported enrollment target (52% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Immune System Diseases appearing as the primary indexed condition, and to 5 interventions - of which GVHD Prophylaxis is the first listed.
NCT03663933 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03663933 about?
NCT03663933 is a clinical study titled "Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation". Background: Blood stem cells in the bone marrow make all the cells to normally defend a body against disease. Allogeneic blood or marrow transplant is when these stem cells are transferred from one person to another. Researchers think this treatment can provide a new, healthy immune system to corre...
What is the current status of trial NCT03663933?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2018-09-04. Estimated completion is 2030-04-03.
What conditions does trial NCT03663933 study?
This clinical trial studies the following conditions: Immune System Diseases, Lymphoproliferative Disorders, Common Variable Immunodeficiency, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders.
What interventions are being tested in trial NCT03663933?
The interventions under investigation include: GVHD Prophylaxis (DRUG), e-ATG (DRUG), Immunosuppression Only Conditioning (PROCEDURE), Reduced Intensity Conditioning (PROCEDURE), Allogeneic HSC (PROCEDURE).
Who is sponsoring clinical trial NCT03663933?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03663933 being conducted?
This trial has 2 study locations across Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
RECRUITING · Phase 2
-
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RECRUITING · Phase 2
-
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
-
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.